HomeComparePKBOW vs JEPQ

PKBOW vs JEPQ: Dividend Comparison 2026

PKBOW yields 20202.02% · JEPQ yields 11.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PKBOW wins by $57988137149625106432.00M in total portfolio value
10 years
PKBOW
PKBOW
● Live price
20202.02%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57988137149625106432.00M
Annual income
$57,428,928,743,751,610,000,000,000.00
Full PKBOW calculator →
JEPQ
JPMorgan Nasdaq Equity Premium Income ETF
● Live price
11.10%
Share price
$55.52
Annual div
$6.16
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.8K
Annual income
$2,152.59
Full JEPQ calculator →

Portfolio growth — PKBOW vs JEPQ

📍 PKBOW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPKBOWJEPQ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PKBOW + JEPQ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PKBOW pays
JEPQ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PKBOW
Annual income on $10K today (after 15% tax)
$1,717,171.72/yr
After 10yr DRIP, annual income (after tax)
$48,814,589,432,188,870,000,000,000.00/yr
JEPQ
Annual income on $10K today (after 15% tax)
$943.83/yr
After 10yr DRIP, annual income (after tax)
$1,829.70/yr
At 15% tax rate, PKBOW beats the other by $48,814,589,432,188,870,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PKBOW + JEPQ for your $10,000?

PKBOW: 50%JEPQ: 50%
100% JEPQ50/50100% PKBOW
Portfolio after 10yr
$28994068574812553216.00M
Annual income
$28,714,464,371,875,805,000,000,000.00/yr
Blended yield
99.04%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PKBOW buys
0
JEPQ buys
0
No recent congressional trades found for PKBOW or JEPQ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPKBOWJEPQ
Forward yield20202.02%11.10%
Annual dividend / share$2.00$6.16
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$57988137149625106432.00M$44.8K
Annual income after 10y$57,428,928,743,751,610,000,000,000.00$2,152.59
Total dividends collected$57951242634511319040.00M$16.3K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: PKBOW vs JEPQ ($10,000, DRIP)

YearPKBOW PortfolioPKBOW Income/yrJEPQ PortfolioJEPQ Income/yrGap
1← crossover$2,030,902$2,020,202.02$11,930$1,110.39+$2.02MPKBOW
2$385,615,342$383,442,277.01$14,133$1,224.34+$385.60MPKBOW
3$68,455,310,249$68,042,701,832.74$16,632$1,340.46+$68455.29MPKBOW
4$11,362,120,801,776$11,288,873,619,809.51$19,454$1,457.97+$11362120.78MPKBOW
5$1,763,290,309,334,738$1,751,132,840,076,837.00$22,626$1,576.08+$1763290309.31MPKBOW
6$255,866,846,080,109,380$253,980,125,449,121,180.00$26,175$1,694.09+$255866846080.08MPKBOW
7$34,717,188,276,404,167,000$34,443,410,751,098,450,000.00$30,133$1,811.32+$34717188276404.14MPKBOW
8$4,404,848,409,251,598,600,000$4,367,701,017,795,846,700,000.00$34,531$1,927.17+$4404848409251598.50MPKBOW
9$522,624,678,386,435,660,000,000$517,911,490,588,536,450,000,000.00$39,403$2,041.08+$522624678386435648.00MPKBOW
10$57,988,137,149,625,104,000,000,000$57,428,928,743,751,610,000,000,000.00$44,787$2,152.59+$57988137149625106432.00MPKBOW

PKBOW vs JEPQ: Complete Analysis 2026

PKBOWStock

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.

Full PKBOW Calculator →

JEPQETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →
📬

Get this PKBOW vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PKBOW vs SCHDPKBOW vs JEPIPKBOW vs OPKBOW vs KOPKBOW vs MAINPKBOW vs XYLDPKBOW vs QYLDPKBOW vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.